Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03850418 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Feb 20, 2026 to Feb 20, 2028v8
  2. Primary completion date: Feb 20, 2025 to Feb 20, 2026v7
  3. Study completion date: Feb 20, 2025 to Feb 20, 2026v6
  4. Primary and study completion dates: Feb 20, 2024 to Feb 20, 2025v5
  5. 2 versions Re-verified since Nov 3, 2020, no change to tracked fieldsv3-v4
  6. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 1, 2019 to Jul 1, 2019
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Previous studies provide a rationale for administration of AZA after allo SCT for decreasing chimerism. The investigators hypothesize that azacitidine can be well tolerated after SCT and help decrease rate of decreasing donor chimerism and hence decrease relapse without increasing GVHD
Trial Details
NCT Number NCT03850418
Lead Sponsor Henry Ford Health System
Conditions
(from sponsor)		 Myeloid Malignancy
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov